Invokana Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Invokana Indications
Indications
Limitations of Use
Not recommended to improve glycemic control in type 1 diabetes. Not recommended in adults with T2DM with an eGFR <30mL/min/1.73m2.
Invokana Dosage and Administration
Adult
Take before first meal of the day. eGFR ≥60mL/min/1.73m2: initially 100mg once daily; may increase to max 300mg once daily for additional glycemic control. eGFR 30–<60mL/min/1.73m2: max 100mg once daily. eGFR <30mL/min/1.73m2: do not initiate, however with albuminuria >300mg/day: may be continued at 100mg once daily (for reducing risk of ESKD, doubling of serum creatinine, CV death, and hospitalization for HF). Concomitant UGT inducers (eGFR ≥60mL/min/1.73m2): increase to 200mg once daily in patients currently tolerating 100mg, max 300mg once daily; (eGFR <60mL/min/1.73m2): increase to max 200mg once daily in patients currently tolerating 100mg once daily.
Children
Invokana Contraindications
Not Applicable
Invokana Boxed Warnings
Not Applicable
Invokana Warnings/Precautions
Warnings/Precautions
Assess renal function prior to starting and as clinically indicated. Prior to initiation, assess and correct volume status in those with renal impairment, elderly, or on loop diuretics; monitor during therapy. Precipitating conditions for diabetic ketoacidosis (acute febrile illness, reduced caloric intake, ketogenic diet, surgery, insulin dose reduction, volume depletion, and alcohol abuse). Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected; evaluate and treat if confirmed. Monitor for resolution of ketoacidosis before restarting. Withhold (at least 3 days), if possible, prior to major surgery or procedures associated with prolonged fasting. Increased risk for lower limb amputations. Consider risk factors that may predispose to amputations prior to initiation (eg, prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers). Monitor for foot infection (including osteomyelitis), new pain or tenderness, sores or ulcers in lower limbs; discontinue if occur. Necrotizing fasciitis of the perineum (Fournier's gangrene); discontinue and treat immediately if suspected; use alternative antidiabetic. Monitor for genital mycotic infections, UTIs (including urosepsis, pyelonephritis); treat if indicated. Discontinue if hypersensitivity reactions occur; treat and monitor until resolved. Consider bone fracture risks before initiation. Renal impairment. Severe hepatic impairment: not recommended. Pregnancy (during 2nd & 3rd trimesters), nursing mothers: not recommended.
Invokana Pharmacokinetics
Absorption
Absolute bioavailability: ~65%.
Distribution
Volume of distribution: 83.5 L. Plasma protein bound: 99%.
Elimination
Invokana Interactions
Interactions
Antagonized by UGT inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir): see Adult dose. Concomitant digoxin: monitor. May need a lower dose of concomitant insulin or insulin secretagogue (eg, sulfonylurea) to reduce risk of hypoglycemia. May antagonize serum lithium concentrations; monitor levels more frequently. May result in false (+) urine glucose tests or unreliable measurements of 1,5-AG assay; use alternative methods to monitor glycemic control.
Invokana Adverse Reactions
Adverse Reactions
Female genital mycotic infections, UTIs (may be serious), increased urination; lower limb amputation, hypotension, ketoacidosis (may be fatal), acute kidney injury, hypoglycemia, bone fractures; rare: Fournier's gangrene.
Invokana Clinical Trials
See Literature
Invokana Note
Not Applicable
Invokana Patient Counseling
See Literature
Images
